Zosyn, Zerbaxa(tazobactam)
Zerbaxa, Zosyn (tazobactam) is a small molecule pharmaceutical. Tazobactam was first approved as Zosyn on 1993-10-22. It has been approved in Europe to treat bacterial infections.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Combinations
Zerbaxa, Zosyn (generic drugs available since 2010-10-21)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ceftolozane sulfate
+
Tazobactam sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZERBAXA | Cubist Pharmaceuticals | N-206829 RX | 2014-12-19 | 1 products, RLD, RS |
Piperacillin sodium
+
Tazobactam sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZOSYN IN PLASTIC CONTAINER | Baxter | N-050750 RX | 1998-02-24 | 3 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| piperacillin and tazobactam | ANDA | 2023-04-25 |
| piperacillin and tazobactam | ANDA | 2023-04-25 |
| zerbaxa | New Drug Application | 2020-09-01 |
| zosyn | New Drug Application | 2023-04-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CEFTOLOZANE SULFATE / TAZOBACTAM SODIUM, ZERBAXA, CUBIST PHARMS LLC | |||
| 2025-04-21 | NPP | ||
| 2024-12-19 | GAIN | ||
| 2019-12-19 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Ceftolozane Sulfate / Tazobactam Sodium, Zerbaxa, Cubist Pharms Llc | |||
| 10125149 | 2035-08-14 | DP | |
| 10376496 | 2034-09-09 | U-2610, U-2611 | |
| 10933053 | 2034-09-09 | U-3090, U-3091 | |
| 8906898 | 2034-05-28 | DS, DP | |
| 8968753 | 2034-03-14 | U-1672, U-1673, U-3360, U-3361 | |
| 9320740 | 2034-03-14 | DP | |
| 9872906 | 2034-03-14 | DP | |
| 10420841 | 2034-03-14 | U-1672, U-2631, U-3360, U-3361 | |
| 11278622 | 2034-03-14 | U-3335, U-3336 | |
| 8476425 | 2032-09-27 | DP | |
| 8685957 | 2032-09-27 | DP | U-36 |
| 9724353 | 2032-09-07 | U-2565, U-2566 | |
| 10028963 | 2032-09-07 | U-2565, U-2566 | |
| 7129232 | 2028-05-15 | DS, DP | U-36, U-1676, U-3360, U-3361 |
| Piperacillin Sodium / Tazobactam Sodium, Zosyn, Wyeth Pharms | |||
| 6900184 | 2023-04-14 | DP | U-282 |
| 7915229 | 2023-04-14 | DP | |
| 8133883 | 2023-04-14 | DP | U-282 |
Clinical
Clinical Trials
119 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | J18 | 2 | 2 | 2 | 1 | 2 | 8 |
| Septic shock | D012772 | A48.3 | — | — | 3 | 2 | 3 | 8 | |
| Sepsis | D018805 | A41.9 | 1 | — | 1 | 2 | 4 | 8 | |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 3 | 4 | 1 | 1 | 8 |
| Bacterial infections | D001424 | A49 | 2 | — | — | 4 | 1 | 7 | |
| Infections | D007239 | EFO_0000544 | 1 | — | 1 | 1 | 3 | 6 | |
| Febrile neutropenia | D064147 | — | 2 | — | 4 | — | 6 | ||
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 3 | 2 | 5 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | 3 | 1 | 4 |
| Enterobacteriaceae infections | D004756 | EFO_1001313 | — | — | — | 3 | 1 | 4 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intraabdominal infections | D059413 | — | 3 | 4 | — | — | 6 | ||
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 3 | 3 | — | — | 5 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 3 | — | 1 | 4 |
| Healthcare-associated pneumonia | D000077299 | 1 | — | 2 | — | — | 3 | ||
| Neoplasms | D009369 | C80 | — | 1 | 1 | — | — | 2 | |
| Leukemia | D007938 | C95 | — | — | 1 | — | 1 | 2 | |
| Lymphoma | D008223 | C85.9 | — | — | 1 | — | 1 | 2 | |
| Surgical wound infection | D013530 | — | — | 1 | — | — | 1 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | 1 | — | — | 1 |
| Pancreatic diseases | D010182 | K86.9 | — | — | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | 1 | 1 | — | — | 2 | 4 | ||
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | 1 | 2 |
| Cross infection | D003428 | — | 1 | — | — | 1 | 2 | ||
| Gastrointestinal microbiome | D000069196 | — | 1 | — | — | — | 1 | ||
| Otitis media | D010033 | EFO_0004992 | H66.9 | 1 | 1 | — | — | — | 1 |
| Graft vs host disease | D006086 | D89.81 | — | 1 | — | — | — | 1 | |
| Communicable diseases | D003141 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | 1 | 5 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neonatal sepsis | D000071074 | HP_0040187 | — | — | — | — | 2 | 2 | |
| Neutropenia | D009503 | D70 | — | — | — | — | 2 | 2 | |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | — | 2 | 2 | ||
| Gram-positive bacterial infections | D016908 | — | — | — | — | 2 | 2 | ||
| Cytokine release syndrome | D000080424 | D89.83 | — | — | — | — | 1 | 1 | |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | — | — | 1 | 1 |
| Chronic bronchitis | D029481 | J42 | — | — | — | — | 1 | 1 | |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Drug monitoring | D016903 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TAZOBACTAM |
| INN | tazobactam |
| Description | Tazobactam is a member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections. It has a role as an antimicrobial agent, an antiinfective agent and an EC 3.5.2.6 (beta-lactamase) inhibitor. It is a member of penicillanic acids and a member of triazoles. It is functionally related to a sulbactam. It is a conjugate acid of a tazobactam(1-). |
| Classification | Small molecule |
| Drug class | beta-lactamase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 89786-04-9 |
| RxCUI | 37617 |
| ChEMBL ID | CHEMBL404 |
| ChEBI ID | 9421 |
| PubChem CID | 123630 |
| DrugBank | DB01606 |
| UNII ID | SE10G96M8W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zosyn - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zerbaxa - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 30,137 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
335 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more